2022 Fiscal Year Final Research Report
Development of technologies using circulating tumor cells for genetic analysis of cancer
| Project/Area Number |
19K07746
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Toyama Industrial Technology Research and Development Center |
|---|
Principal Investigator |
Ohnaga Takashi 富山県産業技術研究開発センター, その他部局等, 副主幹研究員 (10416133)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤井 努 富山大学, 学術研究部医学系, 教授 (60566967)
大塚 基之 東京大学, 医学部附属病院, 届出研究員 (90518945)
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | 血中循環腫瘍細胞 / 遺伝子解析 / シングルセル / ゲル |
|---|
| Outline of Final Research Achievements |
We developed liquid biopsy technologies using circulating tumor cells (CTCs) for genetic analysis of cancer. Cancer cell capture was performed with a microfluidic device “polymer CTC-chip” that we have developed earlier and novel cell recovery methods were developed here. An aqueous monomer mixture was fed to the chip that captured lung cancer cells having known gene mutations, and polymerized to be a gel. A small piece of gel containing the cells could be picked up and the cells were isolated finally by resolving the gel in a PCR tube. The obtained cells were genetically analyzed and the mutation was successfully detected without problems caused by chemicals used for the gel.
|
| Free Research Field |
Liquid Biopsy
|
| Academic Significance and Societal Importance of the Research Achievements |
CTCによる癌の遺伝子解析が可能となれば、低侵襲で継続的に繰り返し患者さんの遺伝子情報を得ることができるようになり、癌の診断、治療、モニタリングに革命的な変化をもたらす。さらに癌が転移能や薬剤耐性などを獲得するプロセスを詳細に解析できるようになり、それらのメカニズム解明、さらには創薬開発へと繋げることが期待できる。またCTCは癌の情報全体を与える成分を有しており、ctDNAなど他のLiquid Biopsyの対象物にはない特徴を有する。以上の点は国が推進する「がんゲノム医療」に大きく寄与するものであり、癌制圧に大きく寄与することが予想される。
|
